Introduction
============

Esophageal cancer, the sixth most common cause of cancer-related death in the world, occurs with increased frequency in specific regions. [@B1] Survival rates for esophageal cancer are poor; 75% of patients die within 1 year after diagnosis, and the 5-year survival rate is only 5-10% .[@B1] The development of esophageal cancer is a multifactorial process associated with a variety of risk factors. Cumulative evidence suggests that tobacco smoking, heavy alcohol drinking, micronutrient deficiency, and dietary carcinogen exposure may cause the disease.[@B2]-[@B5] However, even in the at-risk population, only a portion of exposed individuals develop the cancer in their life span, indicating that there may be important genetic basis rendering such individuals susceptible to the disease.

The tumor-suppressor gene *p53* is important for cellular growth control once the DNA is subject to damage or mutation and arrests the cell cycle in the G1 phase to allow DNA repair or apoptosis.[@B6] Its mutation is widely detected in all types of cancer, including esophageal cancer.[@B6],[@B7] It is now clear that disruption of *p53* pathway, such as through inactivating *p53* mutations, is associated with the formation and progression of malignancies. For example, it has been shown that \>50% of human tumors have inactivating *p53* mutations.[@B8]

Glutathione S-transferase P1 (*GSTP1*) is quantitatively the most important GST isoform in normal esophageal epithelium.[@B9] *GSTP1* expression, *GSTP1* mRNA levels, glutathione content and GST enzyme activities are all reduced in BE (Barrett esophagus) compared with normal esophageal epithelium.[@B9]-[@B13] Because accumulating evidence indicates *p53* and *GSTP1* play central role in cancer formation and progression, one may reason that functional single nucleotide polymorphisms in these genes might render the carrier susceptible to cancer, including esophageal cancer.

It was reported that the *p53* gene is polymorphic and among its single nucleotide polymorphisms, a G\>C change at codon 72 (rs1042522) results in Arg\>Pro amino acid substitution.[@B14] Although both variants are morphologically wild-type, the Pro/Pro genotype is less effective in suppressing cellular transformation.[@B15] Several studies have reported that the *p53* codon 72 polymorphism may be associated with tumor susceptibility to a variety of cancers recently.[@B16]-[@B18] The *GSTP1* gene displays a polymorphism, an A\>G change at codon 105, resulting in an Ile-to-Val substitution (rs1695), which alters the enzymatic activity of the protein.[@B18] This has been suggested as a putative high-risk genotype in various cancers.[@B19] Therefore, it\'s reasonable to hypothesize that the *p53* Arg72Pro and *GSTP1* Ile105Val polymorphisms may functionally related to the risk of esophageal cancer.

A number of molecular epidemiology studies have been conducted to examine the association between *p53* Arg72Pro, *GSTP1* Ile105Val polymorphisms and esophageal cancer susceptibility [@B19]-[@B33], but the results remain inconsistent. To estimate the overall risk of *p53*Arg72Pro, *GSTP1* Ile105Val associated with esophageal cancer risk and to quantify the potential between-study heterogeneity, we conducted a meta-analysis on 13 published case-control studies with 2919 cases and 4074 controls for *p53* Arg72Pro and 1885 cases and 2194 controls for*GSTP1* Ile105Val.

Materials and Methods
=====================

**Identification and Eligibility of Relevant Studies.** We attempted to include all the case-control studies published to date on the association between *p53 Arg72Pro*,*GSTP1* Ile105Val polymorphisms and esophageal cancer risk. Eligible studies were identified by searching the electronic literature PubMed for relevant reports (last search update February 2010, using the search terms "*p53*", "polymorphisms" and "esophageal cancer"; "*GSTP1*"*,* "polymorphisms" and "esophageal cancer"). Additional studies were identified by hands-on searches from references of original studies or review articles on this topic. If studies had partly overlapped subjects, only the one with a larger and/or latest sample size was selected for the analysis.

**Data Extraction.** Two investigators independently extracted data and reached a consensus on all of the items. Data extracted from these articles included the first author\'s name, year of publication, country of origin, ethnicity, number of cases and controls, genotype frequencies for cases and controls.

**Meta-Analysis.** The risk of esophageal cancer associated with *p53* Arg72Pro, *GSTP1* Ile105Val polymorphisms were estimated for each study by odds ratio (OR) with 95% confidence intervals (95%CI). For all studies, we evaluated the risk of the variant genotypes (Pro/Pro, Val/ Val), compared with the wild-type genotype (Arg/Arg, Ile/ Ile). Then we calculated the ORs of the polymorphisms, using both dominant and recessive genetic models of the variant 72Pro and 105Val alleles. In addition, we conducted stratification analysis by ethnicity. The χ^2^-based Q statistic test was used for the assessment of heterogeneity, and it was considered significant for *P* \< 0.05. We used the fixed-effects model and the random-effects model based on the Mantel-Haenszel method and the DerSimonian and Laird method, respectively, to combine values from each of the studies. When the effects were assumed to be homogenous, the fixed-effects model was then used; otherwise, the random-effects model was more appropriate. We also computed the power of the selected studies by using the DSTPLAN4.2 software, in order to assess the probability of detecting an association between *RANTES* polymorphisms and asthma at the 0.05 level of significance, assuming a genotypic risk of 2.0 and 1.5. The Egger\'s test and inverted funnel plots were utilized to provide diagnosis of publication bias (Linear regression analysis, ref.[@B34] All analysis was done by using the Statistical Analysis System software (v.9.1.3, SAS Institute, Cary, NC) and Review Manage (v.4.2). All the *P* values were two-sided.

Results
=======

The selected study characteristics are listed in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. All studies indicated that the distributions of two polymorphism\'s genotypes in the controls were both consistent with Hardy-Weinberg equilibrium except for one study [@B26]for *p53* Arg72Pro, and one studies [@B21] for *GSTP1* Ile105Val. Considering the representation of samples, which may directly result in untruthful effect, we excluded these studies [@B21],[@B26] with a departure from Hardy-Weinberg equilibrium from our analysis. As a result, 6 case-control studies (2919 cases and 4074 controls) for *p53* Arg72Pro and 9 studies (1885 cases and 2194 controls) for*GSTP1* Ile105Val were available for this meta-analysis. The minor Pro allele (for *p53* Arg72Pro) and Val allele (for*GSTP1* Ile105Val) frequency (MAF) were 0.44 and 0.20 for Asian studies, while around 0.60 and 0.32 for Mix and Caucasus populations, respectively.

As shown in Table [3](#T3){ref-type="table"}, the variant homozygote (Pro/Pro) for *p53* Arg72Pro was associated with a significantly increased risk of esophageal cancer (Pro/Pro versus Arg/Arg: OR=1.43, 95%CI=1.23-1.68; P = 0.10 for heterogeneity test) compared with wild-type homozygote (Arg/Arg). We also found significant main effects in the dominant genetic model ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.20, 95%CI=1.06-1.36; P = 0.08 for heterogeneity test; Table [3](#T3){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). However, we failed to find any significant main effects for *GSTP1* Ile105Val on esophageal cancer risk in different genetic models tested (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}).

We further performed stratified analysis according to ethnicity (Asian and Mixed/ Caucasian group). As shown in the Table [4](#T4){ref-type="table"}, we found that the increased esophageal cancer risk associated with *p53* Arg72Pro polymorphism was more evident in Asian ((Pro/Arg +Pro/Pro) versus Arg/Arg: OR=1.35, 95%CI=1.14-1.60, *P*=0.09 for heterogeneity test). Unfortunately, we still failed to find any significant association between *GSTP1* Ile105Val polymorphism and esophageal cancer risk in different ethnicity.

We used Funnel plot and Egger\'s test to access the publication bias of literatures. As shown in Fig. [3](#F3){ref-type="fig"} A, the shape of the funnel plots seemed nonsymmetrical in the dominant genetic model for the *p53* Arg72Pro, suggesting that there was significant publication bias. Egger\'s test was used to provide statistical evidence. As a result, the publication bias was observed slightly for *p53* Arg72Pro (t=4.55, P = 0.01) but was disappeared (t=1.35, P = 0.25) when we excluded the study [@B26] departure from Hardy-Weinberg equilibrium. No publication bias was observed for *GSTP1* Ile105Val (t=1.13, P = 0.29), we also excluded the study [@B21] departure from Hardy-Weinberg equilibrium and still did not found any publication bias for 28C/G (t=0.90, p=0.39).

Discussion
==========

The *GSTP1*gene, which encodes the GST π isoenzyme, is the most important form in the esophagus.[@B35] It can eliminate DNA oxidative products of thymidine or uracil propenal.[@B36] The 105Val form shows altered affinity and enzymatic activity for some substrates.[@B37]-[@B39] However, our analysis results showed there was no significant relations between *GSTP1* Ile105Val polymorphism and esophageal cancer, but this conclusion was consistent with Hiyama T et al\' s review.[@B40] These findings suggest that the *GSTP1* Ile105Val genotype alone does not show any association with the susceptibility to esophageal cancer, even when stratified by subgroup. This finding is perhaps not surprising, because the functional evidence to support the role of *GSTP1* Ile105Val as an esophageal cancer risk factor is not strong. Although *GSTP1* may encode the GST π isoenzyme in the esophagus, positive effect for esophageal cancer frequently has been detected in those who had some environment exposures such as smoke cigarettes, alcohol drinkers or low level of dietary selenium intake. Therefore, it is reasonable to hypothesize that the *GSTP1* Ile105Val polymorphism may be at best a modifier for esophageal cancer by interactive with some lifestyle and dietary habits, but is not a significant independent susceptibility factor.

The *p53* tumor suppressor pathway is well-known to be crucial in maintaining genomic integrity and preventing cells from oncogenic transformation. When a cell is exposed to genotoxic stress such as DNA damage and oncogene activation, the *p53* protein accumulates rapidly through posttranscriptional mechanisms and is also activated as a transcriptional factor, which leads to cell cycle arrest for DNA repair or apoptotic cell death [@B41]. Both mice and humans harboring germ line inactivating mutations in one *p53* allele are highly susceptible to cancer: they develop cancer very early in life and at very high frequencies. [@B42],[@B43]

The functional impact of this *p53* polymorphism has been reported and the Arg/Arg genotype seems to induce apoptosis with faster kinetics and to suppress transformation more efficiently than the Pro/Pro genotype.[@B15] It was shown that *p53* Pro/Pro exhibits a lower ability to induce apoptosis in vitro than *p53*Arg/Arg.[@B15] In a pilot study, Zhang et al.[@B44] showed that subjects carrying the *p53* 72Pro/Pro genotype had a \>2-fold increased risk for developing esophageal cancer. These results are consistent with our present meta-analysis study. Thus, it is reasonable to hypothesize that the Arg72Pro polymorphism with reduced activity of *p53* may play more important role in esophageal cancer risk.

In the present meta-analysis on the association between *p53* Arg72Pro, *GSTP1* Ile105Val polymorphisms and risk of esophageal cancer, we found that variant 72Pro of alleles *p53* Arg72Pro could significantly increase the risk of esophageal cancer, although the association were not significantly evident in most studies individually. However, we failed to find any significant association between *GSTP1* Ile105Val and esophageal cancer risk. In stratified analysis, we further observed that the association between*p53* Arg72Pro and risk of esophageal cancer was remained significant in Asian population. The different effect of *p53* Arg72Pro polymorphism between ethnicity may result from different genetic background and environmental exposures, which may contribute to the frequency of ethnic difference.

It is worth emphasizing that several environment exposures are regarded as risk factors of esophageal cancer, especially tobacco smoking, which is an established etiologic factor for esophageal cancer [@B3],[@B45], and exposure to smoke causes genotoxic stress including DNA damage or avoids potential saturation of enzyme activity.[@B46],[@B47] Several data provided some support for one hypothesis that there may be existed significant interaction between *p53* Arg72Pro or *GSTP1* Ile105Val polymorphism and smoking, though there were not enough report support us to make meta-analysis in current research. Studies with a larger sample size, especially including smoking or another environment factors will be helpful to confirm the findings.

Although there have been consistent findings that the *p53* codon 72 Pro/Pro genotype was associated with increased esophageal SCC risk [@B40], it is worth mentioning that there are 2 main forms of esophageal cancer histologically, squamous cell carcinoma (SCC) and adenocarcinoma, and each has distinct etiologic and pathologic characteristics. Squamous cell is cancer located in epithelial cell of the mouth throat or lungs and adenocarcinoma is composed of cells of glandular tissue. Over the past 5 decades, many changes in the prevalence of esophageal cancer have occurred. Prior to this, SCC comprised more than 95% of esophageal malignancies [@B48]. In our meta-analysis, we had wanted to analysis the association between these two gene polymorphisms and risk of esophageal cancer according to the different pathological type, but most of the included research were majored on SCC, so we failed to conduct related stratified analysis. More molecular epidemiological studies on adenocarcinoma are needed to further elucidate the real association of the*p53* Arg72Pro and *GSTP1* Ile105Val polymorphism with esophageal carcinogenesis.

In conclusion, this meta-analysis of 13 case-control studies provided evidence that the *p53* Arg72Pro polymorphism, but not the *GSTP1* Ile105Val, was significantly associated with increased risk of esophageal cancer, especially in Asian. Further well-designed large studies, particularly referring to gene-gene and gene-environment interactions are warranted to confirm the real contribution of these polymorphisms to esophageal cancer susceptibility.

![ORs (log scale) of esophageal cancer associated with *p53 Arg75Pro* for the Pro/Arg+Pro/Pro genotypes, compared with the Arg/Arg genotype.](ijmsv07p0300g01){#F1}

![ORs (log scale) of esophageal cancer associated with *GSTP1 Ile106Val* for the Ile/Val+Val/Val genotypes, compared with the Ile/Ile genotype.](ijmsv07p0300g02){#F2}

![Funnel plot analysis to detect publication bias in esophageal cancer. Each point represents a separate study for the indicated association. For each study, the OR is plotted on a logarithmic scale against the precision (the reciprocal of the SE).](ijmsv07p0300g03){#F3}

###### 

Characteristics of published studies on *p53*Arg72Pro included in the meta-analysis

  Author (ref\*)   Year   Origin          Ethnicity   SNPsite          Sample size(case/control)   HWE     MAF in controls   Genotypic ORs^&^   Power (%) †   
  ---------------- ------ --------------- ----------- ---------------- --------------------------- ------- ----------------- ------------------ ------------- -------
  Lee JM[@B22]     2000   China(Taiwan)   Asian       *p53* Arg72Pro   90/254                      0.427   0.40              2.56/1.86          37.5          80.2
  Vos M[@B23]      2003   South Afican    African     *p53* Arg73Pro   73/115                      0.216   0.41              0.44/0.96          27.0          63.5
  Hong Y[@B24]     2005   China           Asian       *p53* Arg74Pro   758/1420                    0.105   0.44              1.77/0.99          99.4          100.0
  Cai L[@B25]      2006   China           Asian       *p53* Arg75Pro   204/389                     0.107   0.47              2.25/1.43          64.8          97.7
  Yang W[@B26]     2008   China           Asian       *p53* Arg76Pro   435/550                     0.000   0.32              0.39/0.07          86.0          100.0
  Liu G[@B27]      2009   United States   Caucasian   *p53* Arg77Pro   302/453                     0.066   0.26              1.05/01.18         70.6          99.2
  Canova C[@B19]   2009   European        Caucasian   *p53* Arg78Pro   1492/1443                   0.660   0.73              1.00/0.95          99.6          100.0

\* The ref was referred to the reference numbers in this study.

^&^ data from the same source, so selected by the latest sample size.

^\#^ NA: Not available.

^&^Genotypic odds ratios for homozygotes and heterozygotes.

^†^Power was calculated by the DSTPLAN4.2 software with MAF in controls as the frequency of risk factor, OR was selected 1.5 and 2.0 as the relative risk and а=0.05 as the significance.

###### 

Characteristics of published studies on *GSTP1*I le105Val included in the meta-analysis

  Author (ref\*)          Year   Origin            Ethnicity   SNPsite             Sample size(case/control)   HWE      MAF in controls   Genotypic ORs^&^   Power (%) †   
  ----------------------- ------ ----------------- ----------- ------------------- --------------------------- -------- ----------------- ------------------ ------------- --------
  Lin DX^&^[@B28]         1998   China             Asian       *GSTP1* Ile105Val   42/36                       0.359    0.24              0.25/0.83          12.3          28.9
  Morita S[@B29]          1998   Japan             Asian       *GSTP1* Ile106Val   66/164                      0.412    0.16              0.26/0.19          19.2          49.2
  van Lieshout EM[@B30]   1999   The Netherlands   Caucasian   *GSTP1* Ile107Val   34/247                      0.739    0.23              3.65/3.44          16.4          40.7
  Tan W^&^[@B31]          2000   China             Asian       *GSTP1* Ile108Val   150/150                     0.616    0.22              1.47/0.89          33.5          77.1
  Lee JM[@B22]            2000   China(Taiwan)     Asian       *GSTP1* Ile109Val   90/254                      NA^\#^   NA^\#^            NA^\#^/ NA^\#^     NA^\#^        NA^\#^
  Casson AG[@B21]         2003   Canada            Caucasian   *GSTP1* Ile110Val   45/45                       0.019    0.29              0.78/2.51          14.6          35.1
  Roth MJ[@B32]           2004   China             Asian       *GSTP1* Ile111Val   131/454                     0.057    0.22              0.79/0.88          43.0          88.2
  Casson AG[@B20]         2006   Canada            Caucasian   *GSTP1* Ile112Val   56/95                       0.834    0.35              2.22/1.36          21.7          52.7
  Cai L[@B25]             2006   China             Asian       *GSTP1* Ile113Val   204/393                     0.872    0.18              0.46/0.93          48.4          92.6
  Murphy SJ[@B33]         2007   Irish             Caucasian   *GSTP1* Ile114Val   207/223                     0.201    0.36              0.99/0.93          54.0          94.4
  Canova C[@B19]          2009   European          Caucasian   *GSTP1* Ile115Val   1471/1405                   0.330    0.32              0.97/1.13          99.9          100.0

\* The ref was referred to the reference numbers in this study.

^&^ data from the same source, so selected by the latest sample size.

^\#^ NA: Not available.

^&^Genotypic odds ratios for homozygotes and heterozygotes.

^†^Power was calculated by the DSTPLAN4.2 software with MAF in controls as the frequency of risk factor, OR was selected 1.5 and 2.0 as the relative risk and а=0.05 as the significance.

###### 

Summary ORs of *p53* and *GSTP1* polymorphisms and esophageal cancer risk

  Comparison                      No. of Cases   No. of Controls   OR     95%CI       *P*\*
  ------------------------------- -------------- ----------------- ------ ----------- -------
  *p53 Arg75Pro*                                                                      
  Pro/Arg vs Arg/Arg              1761           2850              1.09   0.95-1.24   0.25
  Pro/Pro vs Arg/Arg              1720           2263              1.43   1.23-1.68   0.06
  Pro/Pro vs (Arg/Arg+Pro/Arg)    2919           4074              1.31   0.95-1.80   0.00
  (Pro/Arg +Pro/Pro) vs Arg/Arg   2919           4074              1.20   1.06-1.36   0.08
  *GSTP1 Ile106Val*                                                                   
  Ile/Val vs Ile/Ile              1687           1917              0.99   0.74-1.32   0.00
  Val/Val vs Ile/Ile              1063           1295              1.00   0,81-1.23   0.28
  Val/Val vs (Ile/Ile+Ile/Val)    1885           2194              0.95   0.79-1.17   0.57
  (Ile/Val+Val/Val) vs Ile/Ile    1885           2194              0.95   0.73-1.25   0.00

\* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test \> 0.05; otherwise, random-effects model was used.

###### 

Association between esophageal cancer risk and the *p53, GSTP1*polymorphisms, stratified by ethnicity.

  SNP site          Studies of available^&^              No. of Cases   No. of Controls   OR^\#^   95%CI       P\*
  ----------------- ------------------------------------ -------------- ----------------- -------- ----------- ------
  p53 Arg72Pro                                                                                                 
  Asian             [@B22],[@B24],[@B25]                 1052           2063              1.35     1.14-1.60   0.09
  Mix               [@B19],[@B23],[@B27]                 1868           2011              1.04     0.86-1.25   0.60
  GSTP1 Ile105Val                                                                                              
  Asian             [@B22],[@B25],[@B29],[@B31],[@B32]   641            1415              0.99     0.66-1.49   0.00
  Caucasian         [@B19],[@B20],[@B30],[@B33]          1768           1970              1.06     0.86-1.31   0.02

^\#^ The OR was obtained in dominant genetic model.

\* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test \> 0.05; otherwise, random-effects model was used.

^&^ Studies of available was referred to the reference resource of the stratified variable, which data was available.
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